Showing 41-50 of 129 results for "".
- FDA Grants Fast Track Designation for Union’s Oral Orismilast for Moderate to Severe HShttps://practicaldermatology.com/news/fda-grants-fast-track-designation-for-unions-oral-orismilast-for-the-treatment-of-moderate-to-severe-hs/2461493/The US Food and Drug Administration (FDA) has granted Fast Track designation to oral orismilast for the treatment of moderate to severe hidradenitis suppurativa (HS). The FDA's Fast Track designation is intended to facilitate the development and review of drug candidates that treat serious conditi…
- Physician Growth Partners Advises MetroDerm PC in Partnership with United Derm Partnershttps://practicaldermatology.com/news/physician-growth-partners-advises-metroderm-pc-in-partnership-with-united-derm-partners/2461277/Physician Growth Partners (PGP) has advised MetroDerm P.C., in its recent partnership with United Derm Partners, a private equity-backed dermatology platform and portfolio company of Seattle-based Frazier Healthcare Partners. This transaction represents an entry point into Atlanta and the greater s…
- ProofPilot Wants You to Submit Research Ideas on Issues Concerning BIPOC Communitieshttps://practicaldermatology.com/news/proofpilot-wants-you-to-submit-research-ideas-on-issues-concerning-bipoc-communities/2461237/ProofPilot, a Software as a Service (SaaS) clinical trial research platform, is rolling out its first ever Open Invitation for Research, in partnership with the nonprofit organization Greater Gift. In advance of Juneteenth and on the heels of its campaign launched in February, ProofPilot is kic…
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous features, the dev…
- Butt First, Endo Launches New Qwo Consumer Campaignhttps://practicaldermatology.com/news/butt-first-endo-launches-new-qwo-consumer-campaign/2461095/Endo International plc is kicking off more than 200 patient events across the United States as part of Butt First, a new direct-to-consumer awareness campaign about Qwo (collagenase clostridium histolyticum-aaes). Qwo received FDA approval in July 2020 and is the first and only injectable treatme…
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties a…
- FDA Fast Tracks Union Therapeutics' AD Candidatehttps://practicaldermatology.com/news/fda-fast-tracks-union-therapeutics-ad-candidate/2460978/The US Food and Drug Administration (FDA) has granted Fast Track designation to Union Therapeutics’ oral orismilast for the treatment of moderate to severe atopic dermatitis (AD). Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory properties also in development for the …
- Additional Data from Incyte's Phase 3 Studies of Topical Ruxolitinibhttps://practicaldermatology.com/news/additional-data-from-incytes-phase-3-studies-of-topical-ruxolitinib/2460774/Findings from three pooled analyses of Incyte’s randomized, double-blind, vehicle-controlled phase 3 studies evaluating ruxolitinib cream add to previously published data for the investigational topical JAK1/JAK2 inhibitor for atopic dermatitis. Presented at the AAD VMX 2021, new findings from TRu…
- Hydrafacial Expands CONNECT Certification Programhttps://practicaldermatology.com/news/hydrafacial-expands-connect-certification-program/2460733/The HydraFacial Company is expanding the HydraFacial CONNECT certification program, making it available to aesthetic professionals nationwide. This past month, the program successfully graduated its first class of CONNECT Masters, the highest distinction in the certification program. HydraFaci…
- Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of ADhttps://practicaldermatology.com/news/medicine-x-launches-eczema-xplained-patient-story-to-drive-understanding-and-awareness-of-ad/2460519/Medicine X today is launching Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most common form of eczema. Each Xplained story follows a real patient and is backed by medical experts and a creative team of artists to bridge the difference between the language heal…